OBJECTIVE: The aim of this study was to assess the association of cardiovascular disease (CVD) risk scores and coronary artery plaque (CAP) progression in HIV-infected participants. METHODS: We studied men with and without HIV-infection enrolled in the Multicenter AIDS Cohort Study (MACS) CVD study. CAP at baseline and follow-up was assessed with cardiac computed tomography angiography (CCTA). We examined the association between baseline risk scores including pooled cohort equation (PCE), Framingham risk score (FRS), and Data collect of Adverse effects of anti-HIV drugs equation (D:A:D) and CAP progression. RESULTS: We studied 495 men (211 HIV-uninfected, 284 HIV-infected). The adjusted odds ratio (aOR) of total plaque volume (TPV) and noncalcified plaque volume (NCPV) progression in the highest relative to lowest tertile was 9.4 [95% confidence interval (95% CI) 2.4-12.1, P < 0.001)] and 7.7 (95% CI 3.1-19.1, P < 0.001) times greater, respectively, among HIV-uninfected men in the PCE atherosclerotic cardiovascular disease (ASCVD) high vs. low-risk category. Among HIV-infected men, the association for TPV and NCPV progression for the same PCE risk categories, odds ratio (OR) 2.8 (95% CI 1.4-5.8, P < 0.01) and OR 2.4 (95% CI 1.2-4.8, P < 0.05), respectively (P values for interaction by HIV = 0.02 and 0.08, respectively). Similar results were seen for the FRS risk scores. Among HIV-uninfected men, PCE high risk category identified the highest proportion of men with plaque progression in the highest tertile, although in HIV-infected men, high-risk category by D:A:D identified the greatest percentage of men with plaque progression albeit with lower specificity than FRS and PCE. CONCLUSION: PCE and FRS categories predict CAP progression better in HIV-uninfected than in HIV-infected men. Improved CVD risk scores are needed to identify high-risk HIV-infected men for more aggressive CVD risk prevention strategies.
OBJECTIVE: The aim of this study was to assess the association of cardiovascular disease (CVD) risk scores and coronary artery plaque (CAP) progression in HIV-infected participants. METHODS: We studied men with and without HIV-infection enrolled in the Multicenter AIDS Cohort Study (MACS) CVD study. CAP at baseline and follow-up was assessed with cardiac computed tomography angiography (CCTA). We examined the association between baseline risk scores including pooled cohort equation (PCE), Framingham risk score (FRS), and Data collect of Adverse effects of anti-HIV drugs equation (D:A:D) and CAP progression. RESULTS: We studied 495 men (211 HIV-uninfected, 284 HIV-infected). The adjusted odds ratio (aOR) of total plaque volume (TPV) and noncalcified plaque volume (NCPV) progression in the highest relative to lowest tertile was 9.4 [95% confidence interval (95% CI) 2.4-12.1, P < 0.001)] and 7.7 (95% CI 3.1-19.1, P < 0.001) times greater, respectively, among HIV-uninfected men in the PCE atherosclerotic cardiovascular disease (ASCVD) high vs. low-risk category. Among HIV-infected men, the association for TPV and NCPV progression for the same PCE risk categories, odds ratio (OR) 2.8 (95% CI 1.4-5.8, P < 0.01) and OR 2.4 (95% CI 1.2-4.8, P < 0.05), respectively (P values for interaction by HIV = 0.02 and 0.08, respectively). Similar results were seen for the FRS risk scores. Among HIV-uninfected men, PCE high risk category identified the highest proportion of men with plaque progression in the highest tertile, although in HIV-infected men, high-risk category by D:A:D identified the greatest percentage of men with plaque progression albeit with lower specificity than FRS and PCE. CONCLUSION: PCE and FRS categories predict CAP progression better in HIV-uninfected than in HIV-infected men. Improved CVD risk scores are needed to identify high-risk HIV-infected men for more aggressive CVD risk prevention strategies.
Authors: Rine Nakanishi; Wendy S Post; Kazuhiro Osawa; Eranthi Jayawardena; Michael Kim; Nasim Sheidaee; Negin Nezarat; Sina Rahmani; Nicholas Kim; Nicolai Hathiramani; Shriraj Susarla; Frank Palella; Mallory Witt; Michael J Blaha; Todd T Brown; Lawrence Kingsley; Sabina A Haberlen; Christopher Dailing; Matthew J Budoff Journal: Coron Artery Dis Date: 2018-01 Impact factor: 1.439
Authors: Markella V Zanni; Kathleen V Fitch; Meghan Feldpausch; Allison Han; Hang Lee; Michael T Lu; Suhny Abbara; Heather Ribaudo; Pamela S Douglas; Udo Hoffmann; Janet Lo; Steven K Grinspoon Journal: AIDS Date: 2014-09-10 Impact factor: 4.177
Authors: T S Metkus; T Brown; M Budoff; L Kingsley; F J Palella; M D Witt; X Li; R T George; L P Jacobson; W S Post Journal: HIV Med Date: 2015-05-13 Impact factor: 3.180
Authors: Angela M Thompson-Paul; Kenneth A Lichtenstein; Carl Armon; Frank J Palella; Jacek Skarbinski; Joan S Chmiel; Rachel Hart; Stanley C Wei; Fleetwood Loustalot; John T Brooks; Kate Buchacz Journal: Clin Infect Dis Date: 2016-09-09 Impact factor: 9.079
Authors: S Parra; B Coll; G Aragonés; J Marsillach; R Beltrán; A Rull; J Joven; C Alonso-Villaverde; J Camps Journal: HIV Med Date: 2009-10-21 Impact factor: 3.180
Authors: Matthew J Budoff; Rebekah Young; Victor A Lopez; Richard A Kronmal; Khurram Nasir; Roger S Blumenthal; Robert C Detrano; Diane E Bild; Alan D Guerci; Kiang Liu; Steven Shea; Moyses Szklo; Wendy Post; Joao Lima; Alain Bertoni; Nathan D Wong Journal: J Am Coll Cardiol Date: 2013-03-26 Impact factor: 24.094